Vaxcyte, Inc. (PCVX) Stock Analysis

Q: What is the PCVX stock price target?

Take-profit $94.83 (+66.5% upside). Prior stop was $54.71.

Q: What are the risks of investing in PCVX?

Concentration risk — Supplier: Sutro Biopharma; Concentration risk — Product: PCV candidates; Quality below floor (1.4 < 4.0); Quality below floor (1.4 < 4.0); Momentum score 2.6/10 — below 4.5 minimum.

Q: Is PCVX overvalued or undervalued?

Vaxcyte, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about PCVX?

17 analysts cover PCVX with a consensus score of 4.3/5. Average price target: $109.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

$56.62+66.5% A.UpsideScore 4.9/10#89 of 158 Biotechnology

Stop $54.71Target $94.83(analyst − 13%)A.R:R 9.0:1

Analyst target$109.00+92.5%9 analysts

$94.83our TP

$56.62price

$109.00mean

$163

Sell if holding. Engine safety override at $56.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 9.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.77; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Supplier: Sutro Biopharma

Concentration risk — Product: PCV candidates

Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.9

Mkt Cap$8.3B

EV/EBITDA-7.5

Profit Mgn0.0%

ROE-25.6%

Rev Growth—

Beta1.39

DividendNone

Rating analysts17

Quality Signals

Piotroski F2/9

Options Flow

P/C5.77bearish

IV78%elevated

Max Pain$50-11.7% vs spot

Concentration Risks(10-K Item 1A)

HIGHSupplierSutro Biopharma
10-K Item 1A: 'the XpressCF® platform exclusively licensed from Sutro Biopharma, Inc. ("Sutro Biopharma") and our proprietary know-how for vaccine applications against infectious disease'
MEDIUMSupplierLonza
10-K Item 1A: 'There can be no assurance that we or Lonza will be able to successfully manufacture drug substances in a timely manner in the future, or at all.'
HIGHProductPCV candidates
10-K Item 1A: 'Our business is highly dependent on the success of our PCV candidates.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.415%0.21

Growth5.015%0.75

Momentum2.610%0.26

Sentiment7.810%0.78

Insider Activity5.010%0.50

Peer Rank4.510%0.45

Technical Setup7.55%0.38

Risk Profile2.25%0.11

Catalyst2.55%0.13

Overall (Σ contributions)4.91

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Moat

5.0

Current Ratio

5.1

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Days To Cover

0.0

Put Call

0.0

Implied Vol

0.3

Debt Equity

0.6

Max Pain Risk

3.0

Volatility

3.3

Short Interest

5.0

Beta

5.5

Elevated put/call: 5.77High IV: 78%Above max pain $50Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 0B/4MEarnings in 6 days

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

4.0

Rsi

8.1

Uptrend pullback (RSI 34) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.6<4.5EARNINGS PROXIMITY 6d<=7dA.R:R 9.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

34 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $56.40Resistance $63.31

Price Targets

$55

$95

A.Upside+67.5%

A.R:R9.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)

! Momentum score 2.6/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

0/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PCVX stock a buy right now?

Sell if holding. Engine safety override at $56.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 9.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.77; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $54.71. Score 4.9/10, moderate confidence.

What is the PCVX stock price target?

Take-profit target: $94.83 (+66.5% upside). Prior stop was $54.71. Stop-loss: $54.71.

What are the risks of investing in PCVX?

Concentration risk — Supplier: Sutro Biopharma; Concentration risk — Product: PCV candidates; Quality below floor (1.4 < 4.0).

Is PCVX overvalued or undervalued?

Vaxcyte, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about PCVX?

17 analysts cover PCVX with a consensus score of 4.3/5. Average price target: $109.

What does Vaxcyte, Inc. do?Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using the...

Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using the XpressCF cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. The company has no product revenue and net losses of $766.6M in 2025; lead candidate VAX-31 (31-valent) is in adult Phase 3 and pediatric development targeting the ~$8B global pneumococcal vaccine market. As of December 31, 2025, cash and investments totaled $2.44B.